Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran etexilate vs enoxaparin for VTE prevention after total hip replacement
2007-002630-11Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabigatran in venous thromboembolism (VTE) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of total venous thromboembolic events and all-cause mortality during the treatment period. Started Feb 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2007-002630-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002630-11.